000270655 001__ 270655
000270655 005__ 20240808164344.0
000270655 0247_ $$2doi$$a10.1007/s00415-024-12469-z
000270655 0247_ $$2pmid$$apmid:38822147
000270655 0247_ $$2pmc$$apmc:PMC11233288
000270655 0247_ $$2ISSN$$a0367-004X
000270655 0247_ $$2ISSN$$a0012-1037
000270655 0247_ $$2ISSN$$a0340-5354
000270655 0247_ $$2ISSN$$a1432-1459
000270655 037__ $$aDZNE-2024-00827
000270655 041__ $$aEnglish
000270655 082__ $$a610
000270655 1001_ $$0P:(DE-2719)9000867$$aPurrer, Veronika$$b0$$eFirst author
000270655 245__ $$aMotor and non-motor outcome in tremor dominant Parkinson's disease after MR-guided focused ultrasound thalamotomy.
000270655 260__ $$aHeidelberg$$bSpringer$$c2024
000270655 3367_ $$2DRIVER$$aarticle
000270655 3367_ $$2DataCite$$aOutput Types/Journal article
000270655 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721644509_12032
000270655 3367_ $$2BibTeX$$aARTICLE
000270655 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000270655 3367_ $$00$$2EndNote$$aJournal Article
000270655 520__ $$aMagnetic Resonance-guided Focused Ultrasound (MRgFUS) is an emerging technique for the treatment of severe, medication-refractory tremor syndromes. We here report motor and non-motor outcomes 6 and 12 months after unilateral MRgFUS thalamotomy in tremor-dominant Parkinson's disease (tdPD).25 patients with tdPD underwent neuropsychological evaluation including standardized questionnaires of disability, quality of life (QoL), mood, anxiety, apathy, sleep disturbances, and cognition at baseline, 6 and 12 months after MRgFUS. Motor outcome was evaluated using the Clinical Rating Scale for Tremor (CRST) and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). In addition, side effects and QoL of family caregivers were assessed.12 months after MRgFUS significant improvements were evident in the tremor subscores. Patients with concomitant rest and postural tremor showed better tremor outcomes compared to patients with predominant rest tremor. There were no differences in the non-motor assessments. No cognitive decline was observed. Side effects were mostly transient (54%) and classified as mild (62%). No changes in the caregivers' QoL could be observed.We found no changes in mood, anxiety, apathy, sleep, cognition or persistent worsening of gait disturbances after unilateral MRgFUS thalamotomy in tdPD. Concomitant postural tremors responded better to treatment than predominant rest tremors.
000270655 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000270655 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000270655 650_2 $$2MeSH$$aHumans
000270655 650_2 $$2MeSH$$aMale
000270655 650_2 $$2MeSH$$aParkinson Disease: therapy
000270655 650_2 $$2MeSH$$aParkinson Disease: complications
000270655 650_2 $$2MeSH$$aParkinson Disease: surgery
000270655 650_2 $$2MeSH$$aFemale
000270655 650_2 $$2MeSH$$aTremor: etiology
000270655 650_2 $$2MeSH$$aTremor: diagnostic imaging
000270655 650_2 $$2MeSH$$aTremor: therapy
000270655 650_2 $$2MeSH$$aTremor: surgery
000270655 650_2 $$2MeSH$$aAged
000270655 650_2 $$2MeSH$$aMiddle Aged
000270655 650_2 $$2MeSH$$aThalamus: diagnostic imaging
000270655 650_2 $$2MeSH$$aThalamus: surgery
000270655 650_2 $$2MeSH$$aQuality of Life
000270655 650_2 $$2MeSH$$aTreatment Outcome
000270655 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000270655 650_7 $$2Other$$aParkinson’s disease
000270655 650_7 $$2Other$$aFocused ultrasound
000270655 650_7 $$2Other$$aNon-motor symptoms
000270655 650_7 $$2Other$$aParkinson’s disease
000270655 650_7 $$2Other$$aThalamotomy
000270655 650_7 $$2Other$$aTremor
000270655 7001_ $$aPohl, Emily$$b1
000270655 7001_ $$aBorger, Valeri$$b2
000270655 7001_ $$aWeiland, Hannah$$b3
000270655 7001_ $$0P:(DE-2719)2810726$$aBoecker, Henning$$b4$$udzne
000270655 7001_ $$0P:(DE-2719)9001551$$aSchmeel, Frederic Carsten$$b5
000270655 7001_ $$0P:(DE-2719)2000056$$aWüllner, Ullrich$$b6$$eLast author$$udzne
000270655 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-024-12469-z$$gVol. 271, no. 7, p. 3731 - 3742$$n7$$p3731 - 3742$$tJournal of neurology$$v271$$x0367-004X$$y2024
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827%20SUP.docx
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827.pdf$$yOpenAccess
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827%20SUP.doc
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827%20SUP.odt
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827%20SUP.pdf
000270655 8564_ $$uhttps://pub.dzne.de/record/270655/files/DZNE-2024-00827.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000270655 909CO $$ooai:pub.dzne.de:270655$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000270655 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000867$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000270655 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810726$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000270655 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001551$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000270655 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000270655 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000270655 9141_ $$y2024
000270655 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000270655 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000270655 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2023-10-21
000270655 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000270655 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000270655 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000270655 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000270655 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x0
000270655 9201_ $$0I:(DE-2719)1011001$$kAG Klockgether$$lPatient Studies$$x1
000270655 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x2
000270655 980__ $$ajournal
000270655 980__ $$aVDB
000270655 980__ $$aUNRESTRICTED
000270655 980__ $$aI:(DE-2719)1011302
000270655 980__ $$aI:(DE-2719)1011001
000270655 980__ $$aI:(DE-2719)1011202
000270655 9801_ $$aFullTexts